On May 15, 2023, a panel of the Inquiry Committee approved a Consent Agreement between BCCNM and the Registrant to address issues that occurred December from 2021 to May 2022 related to diverting narcotics from the facility and from patients on some occasions for personal use while off-duty. The Registrant voluntarily disclosed diversion beyond that identified in a standard audit to a physician. This disclosure ensured that their medical diagnosis and subsequent prognosis and treatment recommendations matched the extent of their substance use disorder, providing a greater likelihood of treatment success. The extent of the disclosure was considered mitigating by the Inquiry Committee panel. The Registrant was diagnosed with and admitted to a disability with a causal relationship to the practice issues via an independent medical report and has agreed to comply with treatment recommendations.
The Registrant has voluntarily agreed to terms equivalent to a limit and/or condition on their practice, including:
One-month suspension.
A limit impacting access to and handling of narcotics, with concurrent medical monitoring, to support the stable return to fitness to practice.
A limit on working overtime, in critical care and as sole nurse for a period of time.
Disclosure of facts and treatment recommendations to relevant employer representative(s).
Regular reports from treating physicians regarding compliance with treatment recommendations.
Remedial education in documentation, professionalism, and ethics.
The Agreement will remain in place for four years of continuous nursing practice.
The name of the Registrant has been withheld in accordance with section 39.3 (4) (a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition.
The Inquiry Committee is satisfied that the terms will protect the public.